Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 01, 2023

SELL
$12.53 - $21.71 $11,277 - $19,539
-900 Reduced 36.0%
1,600 $0
Q4 2022

Feb 07, 2023

SELL
$11.61 - $16.11 $200,853 - $278,703
-17,300 Reduced 87.37%
2,500 $0
Q3 2022

Oct 25, 2022

BUY
$12.21 - $19.7 $168,498 - $271,860
13,800 Added 230.0%
19,800 $5,000
Q2 2022

Aug 04, 2022

SELL
$11.23 - $19.59 $112,300 - $195,900
-10,000 Reduced 62.5%
6,000 $5,000
Q1 2022

Apr 14, 2022

BUY
$13.37 - $17.79 $211,246 - $281,082
15,800 Added 7900.0%
16,000 $35,000
Q2 2021

Jul 19, 2021

SELL
$15.46 - $24.5 $15,460 - $24,500
-1,000 Reduced 83.33%
200 $1,000
Q2 2020

Jul 22, 2020

BUY
$46.7 - $92.04 $14,010 - $27,612
300 Added 33.33%
1,200 $0
Q1 2020

May 07, 2020

SELL
$48.35 - $118.68 $91,865 - $225,492
-1,900 Reduced 67.86%
900 $3,000
Q4 2019

Feb 06, 2020

SELL
$57.36 - $124.1 $321,216 - $694,960
-5,600 Reduced 66.67%
2,800 $95,000
Q3 2019

Oct 28, 2019

BUY
$58.69 - $80.46 $410,830 - $563,220
7,000 Added 500.0%
8,400 $43,000
Q2 2019

Aug 09, 2019

SELL
$77.77 - $120.68 $995,456 - $1.54 Million
-12,800 Reduced 90.14%
1,400 $18,000
Q1 2019

May 10, 2019

BUY
$91.83 - $120.68 $202,026 - $265,496
2,200 Added 18.33%
14,200 $105,000
Q4 2018

Feb 05, 2019

BUY
$85.79 - $126.46 $308,844 - $455,256
3,600 Added 42.86%
12,000 $98,000
Q3 2018

Nov 07, 2018

BUY
$88.49 - $127.55 $460,148 - $663,260
5,200 Added 162.5%
8,400 $273,000
Q2 2018

Aug 10, 2018

BUY
$60.0 - $85.67 $174,000 - $248,443
2,900 Added 966.67%
3,200 $50,000
Q1 2018

May 11, 2018

SELL
$52.72 - $67.25 $263,600 - $336,250
-5,000 Reduced 94.34%
300 $1,000
Q4 2017

Jan 17, 2018

SELL
$58.2 - $72.76 $2.85 Million - $3.56 Million
-48,900 Reduced 90.22%
5,300 $4,000
Q3 2017

Oct 17, 2017

BUY
$57.01 - $118.75 $3.09 Million - $6.44 Million
54,200
54,200 $90,000

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.